Stocklytics Platform
Asset logo for symbol RVMD
REVOLUTION Medicines
RVMD57
$45.14arrow_drop_up4.12%$1.79
High Growth
Asset logo for symbol RVMD
RVMD57

$45.14

arrow_drop_up4.12%

Performance History

Chart placeholder
Key Stats
Open$43.49
Prev. Close$42.46
EPS-3.84
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$7.24B
PE Ratio-
LOWHIGH
Day Range41.67
44.08
52 Week Range15.44
44.80
Ratios
P/B Ratio3.25
Revenue$11.58M
Operating M. %-11,550.31%
Earnings$0.00
Earnings Growth %-75.46%
EBITDA Margin %-1,000.00%
ROE %-36.17%
EPS-3.84

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$948.40
Perf. (24h)
arrow_drop_up1.52%$14.26
Market Cap$841.10B
Price$511.53
Perf. (24h)
arrow_drop_up1.42%$7.17
Market Cap$464.20B
Price$149.88
Perf. (24h)
arrow_drop_up0.12%$0.18
Market Cap$360.27B
Price$127.76
Perf. (24h)
arrow_drop_down0.93%-$1.21
Market Cap$326.65B

About REVOLUTION Medicines (RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark A. Goldsmith Ph.D.
Headquarters
Redwood City
Employees
292
Exchange
NASDAQ
add REVOLUTION Medicines  to watchlist

Keep an eye on REVOLUTION Medicines

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for REVOLUTION Medicines (RVMD)?

For REVOLUTION Medicines (RVMD), the 52-week high is $45.26, which is 0.26% from the current price. The 52-week low is $15.44, the current price is 192.36% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is REVOLUTION Medicines (RVMD) a growth stock?

REVOLUTION Medicines (RVMD) has shown an average price growth of 0.41% over the past three years. It has received a score of 60 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying REVOLUTION Medicines as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is REVOLUTION Medicines 's (RVMD) price per share?

The current price per share for REVOLUTION Medicines (RVMD) is $45.14. The stock has seen a price change of $1.79 recently, indicating a 4.13% change. This reflects the stock's recent market performance and investor sentiment.

help
What is REVOLUTION Medicines (RVMD) stock price performance year to date (YTD)?

As of the latest data, REVOLUTION Medicines (RVMD) has a year-to-date price change of 59.9%. Over the past month, the stock has experienced a price change of 13.59%. Over the last three months, the change has been 27.01%. Over the past six months, the figure is 64.86%.

help
Is REVOLUTION Medicines (RVMD) a profitable company?

REVOLUTION Medicines (RVMD) has a net income of -$436.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 19.61% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -11.55K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $11.58M, although specific revenue growth data is currently not available. The gross profit is $2.27M. Operating income is noted at -$487.18M. Furthermore, the EBITDA is -$522.04M.

help
What is the market capitalization of REVOLUTION Medicines (RVMD)?

REVOLUTION Medicines (RVMD) has a market capitalization of $7.15B. The average daily trading volume is 2.18M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level